Ficin, an enzyme derived from figs latex, has been found to be active against biofilms.
The project is headed by Senior Research Associate of the Microorganism Genetics Lab Ayrat Kayumov and funded by Russian Science Foundation and Project 5-100. The results have been published in Scientific Reports.
KFU and Voronezh State University researchers have used ficin to treat biofilms formed by Staphylococcus, one of the main obstacles in wound treatment.
Dr. Kayumov explains that currently different enzymes are used for wound treatment, such as trypsin, chymotrypsin, or collagenase – they clear wounds from necrotic masses and fibrin clots. He says, “If you treat wounds with an enzyme or protease, healing accelerates. Together with our Voronezh University colleagues we decided to try ficin which has not yet been studied well. It’s worth mentioning that its close analog – papain derived from papaya – has already been introduced abroad. We have used ficin against biofilms and found that it works beautifully. Moreover, it has fared better than trypsin. The complexity of the issue is that in biofilms bacteria are suspended in a matrix like in a jelly, and antibiotics cannot penetrate there. In order for them to become active you have to increase the dosage significantly, sometimes thousand-fold. But it’s reasonable to assume that the effectiveness can increase if the matrix is disrupted”.
The Lab now considers testing other enzymes which can potentially be active against biofilms of various bacteria. Ficin is effective against Staphylococcus films because the latter include many proteins, but biofilms of bacilli, pseudomonades, and E. coli mostly contain polysaccharides, so the protease will not be effective against them.
A plant enzyme’s great advantage is that it’s not cytotoxic – a problem often affecting medications. Plant proteins also are in general less allergenic compared to bacterial or animal proteins. However, ficin has not yet been sufficiently studied and has not been patented as a wound treating agent. Moreover, according to Dr. Kayumov, a technology for the increased enzyme production may be needed.
The team now plans to progress to clinical trials. The enzyme has been so far tested on lab rats.